Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA 2)

3. januar 2008 oppdatert av: Anthera Pharmaceuticals

Phospholipase Levels And Serological Markers of Atherosclerosis 2: An Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease

The study will be conducted at up to 25 U.S. centers and will be a double-blind randomized parallel group placebo controlled study among subjects with stable coronary artery disease (CAD). Subjects will be randomized to receive either placebo tablets or one of 2 orally active doses of A-002. The duration of study drug therapy will be 8 weeks.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

A-002 represents a novel therapy for the treatment of atherosclerosis and coronary artery disease (CAD). Through the inhibition of activity A-002 may provide multifunctional activity directed against key facets of the disease process, namely a) inflammation, b) atherogenic lipid profiles and c) the atherosclerotic process. Non-clinical and clinical data from recent studies have demonstrated the benefit of early and aggressive anti-inflammatory therapy to reduce cardiovascular risk. Recent clinical studies have provided a strong association between levels and cardiovascular event risk. The proposed Phase 2 clinical pharmacology study (Study No. AN-CVD-2222) will examine the effects of 2 different doses of A-002 compared with placebo, on enzyme levels and activity after 8 weeks of treatment. In addition, the effect of treatment on inflammatory markers of cardiovascular risk (C-reactive protein [CRP]), lipid levels and lipoprotein subclasses and other soluble biomarkers (e.g., ICAM-1, VCAM-1, TNF, MCP-1 etc) will also be assessed.

Studietype

Intervensjonell

Registrering (Forventet)

120

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Forente stater
    • Alabama
      • Mobile, Alabama, Forente stater, 36608
        • Mobile Heart Specialists
    • Arizona
      • Scottsdale, Arizona, Forente stater, 85260
        • Sonoran Health Specialists
    • Florida
      • Hudson, Florida, Forente stater, 34667
        • Pasco Cardiology Center
      • Port Charlotte, Florida, Forente stater, 33952
        • Charlotte Cardiovascular Institute
      • Tampa, Florida, Forente stater, 33609
        • Florida Cardiovascular Research Institute
    • Georgia
      • Augusta, Georgia, Forente stater, 30901
        • Augusta Cardiology Clinic
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40207
        • Louisville Cardiology Medical Group
    • Maine
      • Auburn, Maine, Forente stater, 04210
        • Maine Research Associates
    • New York
      • Binghamton, New York, Forente stater, 13901
        • United Medical Associates
      • Syracuse, New York, Forente stater, 13210
        • Cardiology PC
    • Texas
      • Austin, Texas, Forente stater, 78705
        • Austin Heart
    • Virginia
      • Norfolk, Virginia, Forente stater, 23507
        • Clinical Research Associates of Tidewater
    • Wisconsin
      • Madison, Wisconsin, Forente stater, 53715
        • Wisconsin Heart, SC

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Subjects are eligible for inclusion if they meet the following inclusion criteria:

  1. Men and women ≥18 years of age
  2. Written informed consent from the subject
  3. Stable CAD
  4. Stable medical condition, will be compliant and able to comply with the requirements of the protocol

Exclusion Criteria:

Subjects must NOT meet any of the following exclusion criteria:

  1. Planned coronary artery bypass surgery (CABG)
  2. Acute or chronic heart failure as defined by the New York Heart Association (NYHA) classification as functional Class III or Class IV
  3. Hospitalization for acute coronary syndrome (ACS) if troponin >0.1 ng/mL in the preceding 6 weeks
  4. Hospitalization for ST-segment elevation acute myocardial infarction (STEMI) in the preceding 12 weeks
  5. Subjects with chronic inflammatory disease (e.g., rheumatoid arthritis), inflammatory bowel disease, recent (12 weeks) systemic or localized infection (the latter requiring clinical intervention), or major surgery
  6. hs-CRP ≥15 mg/L repeated on at least 2 occasions >24 hours apart due to non-cardiovascular systemic inflammatory conditions (e.g., rheumatoid disease)
  7. Subjects enrolled in another experimental (interventional) protocol within the past 30 days prior to Screening or prior experience with A-002.
  8. Subjects treated for cancer within the previous 5 years except for skin basal cell carcinoma or carcinoma in situ of the cervix, with measures other than a minor, complete surgical excision (e.g., chemotherapy), or radiation therapy
  9. Subjects who have received immunosuppressant therapy within 30 days prior to entry
  10. Subjects who have received anti-tumor necrosis factor (for example, infliximab) therapy within 6 months prior to entry
  11. The presence of severe liver disease with cirrhosis, recent active hepatitis, active chronic hepatitis, ALT or AST >3 x upper limit of normal, biliary obstruction with hyperbilirubinemia (total bilirubin >2 x upper limit of normal)
  12. Active cholecystitis, gall bladder symptoms, or potential hepato-biliary abnormalities
  13. The presence of moderate or severe renal impairment (CrCl <60 mL/min or creatinine >1.5 x upper limit of normal), nephrotic syndrome, or subjects undergoing dialysis
  14. Uncontrolled diabetes mellitus (known HbA1c >11% within the last 1 month prior to screening)
  15. Females who are nursing, pregnant, or intend to become pregnant during the time of the study, or subjects who have a positive serum pregnancy test at Visit 1 (if the subject is a female of child-bearing potential). Women of child-bearing potential must also use a reliable method of birth control during the study and for 1 month following completion of therapy. A reliable method for this study is defined as one of the following: oral or injectable contraceptives, intrauterine device (IUD), contraceptive implants, tubal ligation, hysterectomy, a double-barrier method (diaphragm with spermicidal foam or jelly, or a condom).
  16. Subjects who have a history of alcohol or drug abuse within 1 year of study entry
  17. Subject living too far from participating center or unable to return for follow-up visits
  18. Subjects who in the opinion of the Investigator are a poor medical or psychiatric risk for therapy with an investigational drug, are unreliable, or have an incomplete understanding of the study which may affect their ability to take drugs as prescribed or comply with instructions
  19. Known human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C Virus (HCV) infection
  20. Treatment with any systemic corticosteroid within the 30-day period prior to study entry or the use of inhaled steroids within the 14-day period prior to study entry

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Hva måler studien?

Primære resultatmål

Resultatmål
The primary objective of this study is to determine the effect of once daily (QD) dosing of A-002 on sPLA2 levels and activity

Sekundære resultatmål

Resultatmål
Determine the effect of QD dosing of A-002 on sPLA2 levels and activity at each time point (Weeks 2, 4, and 8)
Compare the effect of QD dosing of A-002 on sPLA2 enzyme levels and markers of inflammation
Determine plasma drug concentrations with QD dosing

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Anthera Pharmaceuticals

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. september 2007

Studiet fullført

1. desember 2007

Datoer for studieregistrering

Først innsendt

4. september 2007

Først innsendt som oppfylte QC-kriteriene

5. september 2007

Først lagt ut (Anslag)

6. september 2007

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

7. januar 2008

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. januar 2008

Sist bekreftet

1. januar 2008

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • AN-CVD2222

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere